Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rho guanine nucleotide exchange factors (RhoGEFs) are proteins that activate Rho GTPases in response to extracellular stimuli and regulate various biologic processes.
ARHGEF19
, one of RhoGEFs, was reported to activate RhoA in the Wnt-
PCP
pathway controlling convergent extension in Xenopus gastrulation. The goal of our study was to identify the role and molecular mechanisms of
ARHGEF19
in the tumorigenesis of non-small cell lung cancer (NSCLC).
ARHGEF19
expression was significantly elevated in NSCLC tissues, and
ARHGEF19
levels were significantly associated with lymph node status, distant metastasis and TNM stage; Patients with high
ARHGEF19
levels had poor overall survival (OS) and progression-free survival (PFS). Our investigations revealed that
ARHGEF19
overexpression promoted the cell proliferation, invasion and metastasis of lung cancer cells, whereas knockdown of this gene inhibited these processes. Mechanistically,
ARHGEF19
activated the mitogen-activated protein kinase (MAPK) pathway in a RhoA-independent manner:
ARHGEF19
interacted with BRAF and facilitated the phosphorylation of its downstream kinase MEK1/2; both the Dbl homology (DH) and Pleckstrin homology (PH) domains of
ARHGEF19
were indispensable for the phosphorylation of MEK1/2. Furthermore, downregulation of miR-29b was likely responsible for the increased expression of
ARHGEF19
in lung cancer tissues and, consequently, the abnormal activation of MAPK signaling. These findings suggest that
ARHGEF19
upregulation, due to the low expression of miR-29 in NSCLC tissues, may play a crucial role in NSCLC tumorigenesis by activating MAPK signaling.
ARHGEF19
could serve as a negative prognostic marker as well as a therapeutic target for NSCLC patients.
...
PMID:ARHGEF19 interacts with BRAF to activate MAPK signaling during the tumorigenesis of non-small cell lung cancer. 2916 15